Compare
Creative Medical Technology Holdings, Inc. vs Senti Biosciences Holdings, Inc. vs Entera Bio Ltd. vs Inmune Bio, Inc.
| Latest fiscal year | Creative Medical Technology Holdings, Inc. CELZ | Senti Biosciences Holdings, Inc. SNTI | Entera Bio Ltd. ENTX | Inmune Bio, Inc. INMB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $6.0K | $22.0K | $42.0K | $50.0K |
| Revenue growth (YoY) | -45.5% | n/a | -76.8% | +257.1% |
| Gross margin | 63.4% | n/a | 0.0% | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$6.00M | -$61.44M | -$11.44M | -$45.93M |
| EPS (Diluted) | -$2.52 | -$2.73 | $0.25 | -$1.86 |
| Operating cash flow | -$5.86M | -$43.44M | -$7.37M | -$22.58M |
| Free cash flow | n/a | -$43.64M | -$7.48M | -$23.62M |
| Cash & equivalents | n/a | $16.42M | $7.11M | $24.75M |
| Total assets | $7.81M | $51.22M | $15.99M | $32.35M |
| Total liabilities | $284.9K | $45.63M | $2.89M | $8.83M |
| Shareholders' equity | $7.51M | $5.59M | $13.10M | $23.52M |
| Return on year-end equity | -79.8% | n/m | -87.3% | -195.3% |
| Shares outstanding | 3.70M | 30.88M | 46.18M | 26.59M |
Revenue, most recent five fiscal years
| Fiscal year | Creative Medical Technology Holdings, Inc. | Senti Biosciences Holdings, Inc. | Entera Bio Ltd. | Inmune Bio, Inc. |
|---|---|---|---|---|
| Latest | $6.0K Ended 2025-12-31 | $22.0K Ended 2025-12-31 | $42.0K Ended 2025-12-31 | $50.0K Ended 2025-12-31 |
| 1 year earlier | $11.0K Ended 2024-12-31 | $0 Ended 2024-12-31 | $181.0K Ended 2024-12-31 | $14.0K Ended 2024-12-31 |
| 2 years earlier | $9.0K Ended 2023-12-31 | $1.98M Ended 2023-12-31 | $0 Ended 2023-12-31 | $155.0K Ended 2023-12-31 |
| 3 years earlier | $88.6K Ended 2022-12-31 | $3.29M Ended 2022-12-31 | $134.0K Ended 2022-12-31 | $374.0K Ended 2022-12-31 |
| 4 years earlier | $87.8K Ended 2021-12-31 | $2.29M Ended 2021-12-31 | $571.0K Ended 2021-12-31 | $181.0K Ended 2021-12-31 |